HK1142593A1 - Pyrrole derivatives as p2y12 antagonists - Google Patents

Pyrrole derivatives as p2y12 antagonists

Info

Publication number
HK1142593A1
HK1142593A1 HK10108967.0A HK10108967A HK1142593A1 HK 1142593 A1 HK1142593 A1 HK 1142593A1 HK 10108967 A HK10108967 A HK 10108967A HK 1142593 A1 HK1142593 A1 HK 1142593A1
Authority
HK
Hong Kong
Prior art keywords
antagonists
pyrrole derivatives
pyrrole
derivatives
Prior art date
Application number
HK10108967.0A
Other languages
English (en)
Inventor
Otmar Klingler
Joerg Czech
Werngard Czechtizky
Tilo Weiss
Melitta Just
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1142593A1 publication Critical patent/HK1142593A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10108967.0A 2007-06-18 2010-09-21 Pyrrole derivatives as p2y12 antagonists HK1142593A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290755 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (1)

Publication Number Publication Date
HK1142593A1 true HK1142593A1 (en) 2010-12-10

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108967.0A HK1142593A1 (en) 2007-06-18 2010-09-21 Pyrrole derivatives as p2y12 antagonists

Country Status (13)

Country Link
US (1) US7910576B2 (zh)
EP (1) EP2167487B1 (zh)
JP (1) JP5371969B2 (zh)
KR (1) KR20100020478A (zh)
CN (1) CN101679358B (zh)
AU (1) AU2008266515B2 (zh)
BR (1) BRPI0812912A2 (zh)
CA (1) CA2690243A1 (zh)
HK (1) HK1142593A1 (zh)
IL (1) IL202758A (zh)
MX (1) MX2009013431A (zh)
MY (1) MY148901A (zh)
WO (1) WO2008155022A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004048A (es) 2006-10-20 2009-04-27 Novartis Ag Modificaciones de cristal de la 3-(1h-indol-3-il)-4-[2-(4-metil-pi perazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona.
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CA3134635A1 (en) 2019-04-03 2020-10-08 Aligos Therapeutics, Inc. Pyrrole compounds
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
PL377053A1 (pl) 2002-12-11 2006-01-23 Schering Aktiengesellschaft Związki 2-aminokarbonylo-chinoliny jako antagonisty receptora płytkowego difosforanu adenozyny
KR20060041254A (ko) 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
US7273881B2 (en) * 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法
US20090227555A2 (en) * 2005-01-06 2009-09-10 Astrazeneca Ab Novel Pyridine Compounds
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
JP2008534570A (ja) * 2005-03-28 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害薬としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
ATE540034T1 (de) * 2005-11-03 2012-01-15 Portola Pharm Inc Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren
US20070259879A1 (en) * 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Also Published As

Publication number Publication date
US20100226918A1 (en) 2010-09-09
AU2008266515B2 (en) 2014-05-01
JP2010530380A (ja) 2010-09-09
EP2167487A1 (en) 2010-03-31
AU2008266515A1 (en) 2008-12-24
MY148901A (en) 2013-06-14
MX2009013431A (es) 2010-01-15
CN101679358B (zh) 2013-10-30
WO2008155022A1 (en) 2008-12-24
CN101679358A (zh) 2010-03-24
IL202758A (en) 2013-09-30
IL202758A0 (en) 2010-06-30
KR20100020478A (ko) 2010-02-22
EP2167487B1 (en) 2015-02-18
JP5371969B2 (ja) 2013-12-18
BRPI0812912A2 (pt) 2014-12-09
CA2690243A1 (en) 2008-12-24
US7910576B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
HK1141803A1 (en) Quinoline-carboxamide derivatives as p2y12 antagonists
HK1149756A1 (en) Isoxazolo-pyridine derivatives
IL210176A0 (en) Substituted pyrimidone derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
EP2120569A4 (en) SPIROCHROMANONDERIVATE
HK1157756A1 (en) Pyrrole compounds
HK1148286A1 (en) Aminopyrazole derivatives
IL202020A0 (en) Spiroindolinone derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
IL202830A0 (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201008053B (en) Substituted 2-phenyl-pyridine derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
HK1215434A1 (zh) 取代的嘧啶衍生物
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2133347A4 (en) 1-BIARYLAZETIDINONDERIVATE
HK1142593A1 (en) Pyrrole derivatives as p2y12 antagonists
HK1141009A1 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
HK1146276A1 (en) Thiadiazinone derivatives
EP2204368A4 (en) 4-SULFONYLPIPERIDINE DERIVATIVES
HU0700417D0 (en) Sulfonyl-quinoline derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180604